New uncured pepperoni developed in response to consumer demand for premium, versatile deli meats AUSTIN, Minn. , July 1, 2025 /PRNewswire/ -- COLUMBUS® Craft Meats, a leading brand in premium salumi, has launched its first standalone pepperoni deli product: COLUMBUS® Uncured Pepperoni. A brand rooted in Italian American tradition, the COLUMBUS ® brand recognized an opportunity to bring bold, elevated pepperoni to the deli, crafted for consumers craving premium flavor and versatility. COLUMBUS® Craft Meats, ...

Ghingo will join Hormel Foods' board of directorsEttinger's role to conclude after 15 monthsAUSTIN, Minn., June 23, 2025 /PRNewswire/ -- Hormel Foods Corporation (NYSE: HRL), a Fortune 500 global branded food company, today announced that John Ghingo will be promoted to the role of president, becoming the 11th person to hold the position in the company's nearly 135-year history. Jeffrey M. Ettinger, current member of the Hormel Foods board, will return to the company for a defined period of 15 months as int ...

Award-winning internship program offers students from 50 colleges and universities three months of hands-on business experience AUSTIN, Minn., May 27, 2025 /PRNewswire/ -- It's more than an internship — it's a launchpad to a rewarding career. Typically, more than 70% of Hormel Foods interns become full-time team members at the company. Starting today, the company will welcome over 95 students from 50 colleges and universities across the country. The award-winning Hormel Foods summer internship program o ...

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 近日， 剑虎医疗科技（苏州）有限公司 （简称" 剑虎医疗 "）自主研发的 心脏电生理三维标测系统 —— StarTrek ® 正式获得国家药品监督管理局（NMPA）批准上市。 这标志着国产电生理领域取得重大突破，为心脏电生理治疗提供了全新的解决方案。 # 研发背景 房颤 是心律失常领域最为常见的疾病之一，属于快速室上性心律失常，其显著特点是心房活动紊乱、不协 调。当房颤发作时，心房会快速且不规则地跳动，频率高达 3 00～600次/分 ，患者往往会出现心悸、眩 晕、胸闷不适以及气短等症状。 心未来 根据公开资料显示，中国房颤患者人数 近 2000万 ，与冠心病患者人数相当，手术量却相距甚远。 2020年房颤手术总量 约7万例 ，同年冠脉介入手术量却已达到100多万例。 三维标测技术 从大约三十年前诞生的LocaLisa纯电场标测系统，发展到本世纪初圣犹达（ 雅培 ）的电场标 测 ...

Core Viewpoint - The electrophysiology device market in China is experiencing rapid growth due to an aging population, increasing prevalence of arrhythmias, improved early screening rates, and advancements in electrophysiological procedures, with the market expected to reach over 40 billion yuan by 2032 [1][10][21]. Industry Overview - Electrophysiology devices are used to monitor and study electrical activities in biological systems, widely applied in medical, research, and clinical diagnosis fields. Common products include ECG machines, EEG machines, EMG machines, and electrophysiological navigation systems [2][4]. Industry Environment - The number of patients with rapid arrhythmias in China is projected to reach 28.2 million by 2024, driving demand for treatment. Electrophysiological surgeries have become a primary treatment method due to their advantages such as minimal invasiveness and high safety [6][8]. Industry Status - The market size for electrophysiology devices in China has grown from 2.42 billion yuan in 2017 to 12.55 billion yuan in 2024. The surgical volume for electrophysiology has increased from 138,000 cases in 2017 to 456,000 cases in 2024, indicating significant growth potential [10][8]. Competitive Landscape - The market is dominated by foreign companies such as Johnson & Johnson, Abbott, and Medtronic, which hold a combined market share of over 64%. Domestic companies like Huatai Medical and MicroPort EP have a much smaller share, indicating a high concentration in the industry [12][14]. Key Enterprises - MicroPort EP focuses on innovative medical devices for electrophysiology and has achieved significant revenue growth, with a projected income of 413 million yuan in 2024, up 25.51% [17]. Huatai Medical, specializing in electrophysiology and interventional medical devices, expects a revenue of 440 million yuan in 2024, reflecting a 19.73% increase [19]. Development Trends 1. **Accelerated Domestic Substitution**: Domestic brands are gaining market share due to supportive policies and technological advancements, with MicroPort EP and Huatai Medical leading in key areas [21]. 2. **Technological Innovation**: The industry is moving towards smart and precise technologies, enhancing the performance of electrophysiology devices and expanding clinical applications [22]. 3. **Growing Market Demand**: The demand for electrophysiology devices is surging, particularly in grassroots healthcare and international markets, with significant growth in overseas revenues for domestic companies [23].

Core Insights - Hormel Foods Corporation announced that Jeff Baker will become the group vice president for Retail marketing at the end of fiscal 2025, succeeding Scott Aakre [1] - Baker has been with Hormel Foods for 35 years, holding various positions in sales, product management, and marketing, demonstrating a strong track record of growth [2][3] - The company aims to evolve its brand portfolio to align with changing consumer preferences, enhance its presence in snacking and entertaining, and drive growth in its food-forward portfolio under Baker's leadership [1][3] Company Overview - Hormel Foods Corporation is a global branded food company based in Austin, Minnesota, with approximately $12 billion in annual revenue and operations in over 80 countries [3] - The company’s brand portfolio includes well-known names such as PLANTERS®, SKIPPY®, SPAM®, and HORMEL® NATURAL CHOICE®, among others [3] - Hormel Foods is recognized as a member of the S&P 500 Index and has received various accolades for corporate responsibility and community service [3]

近日，微电生理（688351.SH）发布了2025年一季度业绩报告，亮出摘U后首张业绩成绩单。今年一季 度，微电生理实现营业收入1.04亿元，同比增长16.77%；归母净利润1787.05万元，同比增长328.63%； 归母扣非后净利润也实现正盈利至1256.03万元。作为国内电生理龙头，公司延续了强劲的增长势头， 展现出极佳的业绩韧性和发展潜力。 微电生理PFA完成商业化落子，三款产品进入"绿色通道" 截至2024年，微电生理已围绕Columbus®三维心脏电生理标测系统形成30余款已取得注册证的产品，三 维消融系列产品自上市以来累计手术量超过70000例。 2025年，微电生理凭借深厚的技术积累和持续的创新能力，正在加速产品管线的布局与突破，并在电生 理领域实现"冰、火、电、磁"产品管线全面商业化。尤其是在今年4月1日，其参股公司商阳医疗PFA产 品获批后，微电生理便已补齐三大能量平台商业化版图中最后一块"电"拼图；此外，公司自主研发的 PulseMagic™压力脉冲导管也已进入国家药监局特别审查程序"绿色通道"，目前已完成多中心临床试 验，预计2025年获批。 不仅如此，继PulseMagic™压力脉冲 ...